# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0000000000-26-001525
**Filing Date:** 2026-2
**Character Count:** 2299
**Document Hash:** f39d0d330c7fc9a207c35fcb097db2ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001525.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0000000000-26-001525

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260212

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AEON Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293309

**BUSINESS ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614
- **BUSINESS PHONE:** (949) 354-6499

**MAIL ADDRESS:**
- **STREET 1:** 5 PARK PLAZA
- **STREET 2:** SUITE 1750
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92614

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Priveterra Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201222
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-26-012105

## Text-Extract

```

                                                           February 12, 2026

Robert Bancroft
President and Chief Executive Officer
AEON Biopharma, Inc.
5 Park Plaza
Suite 1750
Irvine, CA 92614

       Re: AEON Biopharma, Inc.
           Registration Statement on From S-3
           Filed February 09, 2026
           File No. 333-293309
Dear Robert Bancroft:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Drew Capurro, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._